A citation-based method for searching scientific literature

Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, Giuseppe Bellastella, Maria Ida Maiorino, Katherine Esposito. Cardiovasc Diabetol 2021
Times Cited: 8







List of co-cited articles
13 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
37

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
37

GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off.
Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, Giuseppe Bellastella, Katherine Esposito. Cardiovasc Diabetol 2021
5
40


The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
Alessandro Liberati, Douglas G Altman, Jennifer Tetzlaff, Cynthia Mulrow, Peter C Gøtzsche, John P A Ioannidis, Mike Clarke, P J Devereaux, Jos Kleijnen, David Moher. Ann Intern Med 2009
25

GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs.
Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, Paola Caruso, Maria Ida Maiorino, Giuseppe Bellastella, Antonio Ceriello, Paolo Chiodini, Katherine Esposito. Cardiovasc Diabetol 2021
19
25

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
25

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
25

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetes Care 2020
483
25

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Mikhail Kosiborod, Carolyn S P Lam, Shun Kohsaka, Dae Jung Kim, Avraham Karasik, Jonathan Shaw, Navdeep Tangri, Su-Yen Goh, Marcus Thuresson, Hungta Chen,[...]. J Am Coll Cardiol 2018
258
25

SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials.
Wen-Jie Li, Xing-Qing Chen, Ling-Ling Xu, Yuan-Qing Li, Bi-Hui Luo. Cardiovasc Diabetol 2020
37
25

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.
N Sarwar, P Gao, S R Kondapally Seshasai, R Gobin, S Kaptoge, E Di Angelantonio, E Ingelsson, D A Lawlor, E Selvin, M Stampfer,[...]. Lancet 2010
25

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
25



Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis.
Yue Fei, Man-Fung Tsoi, Bernard Man Yung Cheung. Cardiovasc Diabetol 2019
75
12


Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.
Maria Ida Maiorino, Miriam Longo, Lorenzo Scappaticcio, Giuseppe Bellastella, Paolo Chiodini, Katherine Esposito, Dario Giugliano. Cardiovasc Diabetol 2021
8
12


Bias in meta-analysis detected by a simple, graphical test.
M Egger, G Davey Smith, M Schneider, C Minder. BMJ 1997
12

Evolving Concepts of Type 2 Diabetes Management.
Layla A Abushamat, Jane E B Reusch. Med Clin North Am 2021
1
100

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022.
Boris Draznin, Vanita R Aroda, George Bakris, Gretchen Benson, Florence M Brown, RaShaye Freeman, Jennifer Green, Elbert Huang, Diana Isaacs, Scott Kahan,[...]. Diabetes Care 2022
57
12

Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with/without albuminuria: A systematic review and network meta-analysis.
Yuki Kawai, Kazushi Uneda, Takayuki Yamada, Sho Kinguchi, Kazuo Kobayashi, Kengo Azushima, Tomohiko Kanaoka, Yoshiyuki Toya, Hiromichi Wakui, Kouichi Tamura. Diabetes Res Clin Pract 2022
2
50

Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus.
Harshal R Patil, Firas J Al Badarin, Hamza A Al Shami, Salman K Bhatti, Carl J Lavie, David S H Bell, James H O'Keefe. Am J Cardiol 2012
118
12


SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.
Emily Brown, Hiddo J L Heerspink, Daniel J Cuthbertson, John P H Wilding. Lancet 2021
41
12


Diabetes and Cardiovascular Disease: an Update.
Rajaa Almourani, Bhavana Chinnakotla, Richa Patel, L Romayne Kurukulasuriya, James Sowers. Curr Diab Rep 2019
21
12

Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association.
Salim S Virani, Alvaro Alonso, Emelia J Benjamin, Marcio S Bittencourt, Clifton W Callaway, April P Carson, Alanna M Chamberlain, Alexander R Chang, Susan Cheng, Francesca N Delling,[...]. Circulation 2020
12

Efficacy of SGLT-2 inhibitors in older adults with diabetes: Systematic review with meta-analysis of cardiovascular outcome trials.
Dario Giugliano, Miriam Longo, Maria Ida Maiorino, Giuseppe Bellastella, Paolo Chiodini, Sebastiano Bruno Solerte, Katherine Esposito. Diabetes Res Clin Pract 2020
19
12

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.
Julian P T Higgins, Douglas G Altman, Peter C Gøtzsche, Peter Jüni, David Moher, Andrew D Oxman, Jelena Savovic, Kenneth F Schulz, Laura Weeks, Jonathan A C Sterne. BMJ 2011
12

Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people.
Anoop Dinesh Shah, Claudia Langenberg, Eleni Rapsomaniki, Spiros Denaxas, Mar Pujades-Rodriguez, Chris P Gale, John Deanfield, Liam Smeeth, Adam Timmis, Harry Hemingway. Lancet Diabetes Endocrinol 2015
558
12

2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
Sandeep R Das, Brendan M Everett, Kim K Birtcher, Jenifer M Brown, William T Cefalu, James L Januzzi, Rita Rastogi Kalyani, Mikhail Kosiborod, Melissa L Magwire, Pamela B Morris,[...]. J Am Coll Cardiol 2018
190
12

Intracellular Na+ Concentration ([Na+]i) Is Elevated in Diabetic Hearts Due to Enhanced Na+-Glucose Cotransport.
Rebekah Lambert, Sarah Srodulski, Xiaoli Peng, Kenneth B Margulies, Florin Despa, Sanda Despa. J Am Heart Assoc 2015
64
12

Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure.
Nikole J Byrne, Nobutoshi Matsumura, Zaid H Maayah, Mourad Ferdaoussi, Shingo Takahara, Ahmed M Darwesh, Jody L Levasseur, James Won Suk Jahng, Dyonne Vos, Nirmal Parajuli,[...]. Circ Heart Fail 2020
74
12

Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium.
Donato Cappetta, Antonella De Angelis, Loreta Pia Ciuffreda, Raffaele Coppini, Anna Cozzolino, Agostino Miccichè, Carmela Dell'Aversana, Domenico D'Amario, Eleonora Cianflone, Cristina Scavone,[...]. Pharmacol Res 2020
38
12

Intracellular Na(+) concentration is elevated in heart failure but Na/K pump function is unchanged.
Sanda Despa, Mohammed A Islam, Christopher R Weber, Steven M Pogwizd, Donald M Bers. Circulation 2002
243
12


Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers.
Lin-Zhi Chen, Arvid Jungnik, Yanping Mao, Elsy Philip, Dale Sharp, Anna Unseld, Leo Seman, Hans-Jürgen Woerle, Sreeraj Macha. Xenobiotica 2015
14
12

Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects.
Abdullah Kaplan, Emna Abidi, Ahmed El-Yazbi, Ali Eid, George W Booz, Fouad A Zouein. Heart Fail Rev 2018
58
12

Empagliflozin enhances human and murine cardiomyocyte glucose uptake by increased expression of GLUT1.
Julian Mustroph, Charlotte M Lücht, Olivia Wagemann, Thomas Sowa, Karin P Hammer, Can M Sag, Daniel Tarnowski, Andreas Holzamer, Steffen Pabel, Bo Eric Beuthner,[...]. Diabetologia 2019
10
12

Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation.
Yumei Ye, Xiaoming Jia, Mandeep Bajaj, Yochai Birnbaum. Cardiovasc Drugs Ther 2018
39
12

Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia.
Mohammed Ali Azam, Praloy Chakraborty, Daoyuan Si, BeiBei Du, Stéphane Massé, Patrick F H Lai, Andrew C T Ha, Kumaraswamy Nanthakumar. Life Sci 2021
11
12

Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins.
Sin-Hee Park, Eugenia Belcastro, Hira Hasan, Kensuke Matsushita, Benjamin Marchandot, Malak Abbas, Florence Toti, Cyril Auger, Laurence Jesel, Patrick Ohlmann,[...]. Cardiovasc Diabetol 2021
17
12

Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1/MAPK signaling.
Ke Lin, Na Yang, Wu Luo, Jin-Fu Qian, Wei-Wei Zhu, Shi-Ju Ye, Chen-Xin Yuan, Di-Yun Xu, Guang Liang, Wei-Jian Huang,[...]. Acta Pharmacol Sin 2022
1
100

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits.
Antonius Baartscheer, Cees A Schumacher, Rob C I Wüst, Jan W T Fiolet, Ger J M Stienen, Ruben Coronel, Coert J Zuurbier. Diabetologia 2017
313
12

Na+ controls hypoxic signalling by the mitochondrial respiratory chain.
Pablo Hernansanz-Agustín, Carmen Choya-Foces, Susana Carregal-Romero, Elena Ramos, Tamara Oliva, Tamara Villa-Piña, Laura Moreno, Alicia Izquierdo-Álvarez, J Daniel Cabrera-García, Ana Cortés,[...]. Nature 2020
65
12

Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation.
Laween Uthman, Antonius Baartscheer, Boris Bleijlevens, Cees A Schumacher, Jan W T Fiolet, Anneke Koeman, Milena Jancev, Markus W Hollmann, Nina C Weber, Ruben Coronel,[...]. Diabetologia 2018
254
12

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.
B Komoroski, N Vachharajani, D Boulton, D Kornhauser, M Geraldes, L Li, M Pfister. Clin Pharmacol Ther 2009
251
12

Laminar Flow on Endothelial Cells Suppresses eNOS O-GlcNAcylation to Promote eNOS Activity.
Sarah E Basehore, Samantha Bohlman, Callie Weber, Swathi Swaminathan, Yuji Zhang, Cholsoon Jang, Zoltan Arany, Alisa Morss Clyne. Circ Res 2021
3
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.